Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joint ( (JYNT) ) has issued an update.
The Joint Corp. reported its second quarter 2025 financial results, highlighting a 5% revenue growth to $13.3 million and a significant improvement in net income from a loss of $3.6 million in Q2 2024 to a profit of $93,000. The company refranchised 37 clinics, acquired rights to the Northwest regional developer territory, and increased its franchised clinics to 92% of its portfolio. The company is focusing on enhancing its brand campaign and improving its marketing infrastructure to drive long-term sales, while also planning nominal price increases to balance affordability and patient value.
The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
Spark’s Take on JYNT Stock
According to Spark, TipRanks’ AI Analyst, JYNT is a Neutral.
Joint Corp.’s overall score reflects financial challenges, including profitability issues and bearish technical indicators. However, strategic initiatives and recent corporate events provide a positive outlook for future growth and profitability, balancing the current financial struggles.
To see Spark’s full report on JYNT stock, click here.
More about Joint
The Joint Corp. is a national operator, manager, and franchisor of chiropractic clinics. The company focuses on providing chiropractic services through a network of franchised and corporate clinics, with a significant emphasis on expanding its franchise operations.
Average Trading Volume: 61,065
Technical Sentiment Signal: Strong Sell
Current Market Cap: $171.2M
See more data about JYNT stock on TipRanks’ Stock Analysis page.